We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Rukobia

News List

ViiV’s Rukobia receives marketing authorisation in Europe for HIV treatment pharmaceutical-technology
February 10, 2021
GlaxoSmithKline’s (GSK) ViiV Healthcare has announced the European Marketing Authorisation of its Rukobia (fostemsavir) 600mg extended-release tablets for use in combination with antiretroviral (ARV) therapies for treating adults with ...
US FDA approves GSK’s HIV drug for patients with limited options expresspharma
July 06, 2020
The oral treatment from the company’s HIV unit, ViiV Healthcare, has been approved for adults whose HIV infection could not be successfully treated with other therapies due to resistance, intolerance or safety considerations.
FDA approves ViiV's novel HIV treatment Rukobia pharmatimes
July 03, 2020
The US Food and Drug Administration (FDA) has approved ViiV Healthcare's novel attachment inhibitor Rukobia (fostemsavir) expanding treatment options for HIV.